BENODANIL


UNII	993ANP6B3R
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	LJOZMWRYMKECFF-UHFFFAOYSA-N
Smiles	Ic1ccccc1C(=O)Nc2ccccc2
InChI	InChI=1S/C13H10INO/c14-12-9-5-4-8-11(12)13(16)15-10-6-2-1-3-7-10/h1-9H,(H,15,16)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C13H10INO
Molecular Weight	323.13
AlogP	3.19
Hydrogen Bond Acceptor	1.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	2.0
Polar Surface Area	29.1
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	16.0

Assay Description	Organism	Bioactivity
Antifungal activity against logarithmic phase of Botryotinia fuckeliana ATCC 48339 assessed as growth inhibition measured at 5 days post-drug treatment	Botryotinia fuckeliana	66000.0 nM
Antifungal activity against logarithmic phase of Botryotinia fuckeliana ATCC 48339 assessed as growth inhibition at 100 ug/ml measured at 5 days post-drug treatment	Botryotinia fuckeliana	97.6 %
Antifungal activity against logarithmic phase of Botryotinia fuckeliana ATCC 48339 assessed as growth inhibition at 50 ug/ml measured at 5 days post-drug treatment	Botryotinia fuckeliana	91.2 %
Antifungal activity against logarithmic phase of Botryotinia fuckeliana ATCC 48339 assessed as growth inhibition at 10 ug/ml measured at 5 days post-drug treatment	Botryotinia fuckeliana	6.3 %

Cross References

Resources	Reference
ChEMBL	CHEMBL1357627
FDA SRS	993ANP6B3R
PDB	BOL
PubChem	27195
SureChEMBL	SCHEMBL18736
ZINC	ZINC00061524

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).